Table 1.
Clinical and histopathological variables of all ten cohorts.
| Clinical variables | Study cohort | IHC cohort | Erho et al. | TCGA-PRAD | CAM Ross-Adams et al. |
|---|---|---|---|---|---|
| Samples (patients) | 156 (41) | 40 (40) | 545 (545) | 549 (497) | 186 (163) |
| Cancer samples (patients) | 116 (41) | 40 (40) | 545 (545) | 497 (497) | 112 (112) |
| Age at diagnosis, years (median, range) | 64 (48–69) | 61 (48–73) | 65.3 ± 6.4 | 61 (41–78) | 61 (41–73) |
| PSA before surgery, ng/mL (median, range) | 9.1 (4.0–45.8) | 8.85 (5.2–18) | — | 7.4 (0.7–107) | 7.8 (3.2–23.7) |
| Grade Groups | |||||
| Low (1–2) | 60 (52%) | 19 (47.5%) | 334 (61%)a | 207 (42%) | 82 (73%) |
| High (3–5) | 56 (48%) | 21 (52.5%) | 211 (39%)a | 289 (58%) | 30 (27%) |
| Pathological T stage | |||||
| pT1 | — | — | — | — | — |
| pT2 | 70 (60%) | 27 (68%) | 219 (40%) | 187 (38%) | 33 (29%) |
| pT3 | 40 (35%) | 12 (30%) | 253 (47%) | 293 (59%) | 74 (66%) |
| pT4 | — | — | 9 (2%) | 1 (1%) | |
| No data | 6 (5%) | 1 (2%) | 73 (13%) | 8 (1%) | 4 (4%) |
| Follow-up | |||||
| Endpoint | BCR | BCR | Metastasis | BCR | Recurrence |
| Occurred | 13 (32%) | 16 (40%) | 212 (39%)b | 91 (18%) | 19 (17%) |
| Not occurred | 21 (51%) | 21 (53%) | 333 (69%)b | 399 (80%) | 93 (83%) |
| No data | 7 (17%) | 3 (8%) | — | 7 (2%) | — |
| Clinical variable | STK Ross-Adams et al. | Wang et al. | Sboner et al. | Taylor et al. | Mortensen et al. |
| Samples (patients) | 94 (94) | 136 (82) | 281 (281) | 160 (131) | 50 (50) |
| Cancer samples (patients) | 94 (94) | 65 (56) | 281 (281) | 131 (131) | 36 (36) |
| Age years (median, range) | 63 (43–77) | 74 (51–91) | 58 (37–73) | 63 (46–71) | |
| PSA before surgery, ng/mL (median, range) | 7.95 (1.5–117) | 6.62 (1.0–75) | 5.92 (1.0–46) | 16 (5.0–43) | |
| Grade Groups | |||||
| Low (1–2) | 60 (64%) | 50 (77%) | 162 (58%) | 107 (82%) | 32 (89%)a |
| High (3–5) | 34 (36%) | 15 (23%) | 119 (42%) | 24 (18%) | 4 (11%)a |
| Pathological T-stage | |||||
| pT1 | — | 1 (2%) | 281c (100%) | — | — |
| pT2 | 48 (51%) | 32 (57%) | — | 85 (65%) | 19 (53%) |
| pT3 | 42 (45%) | 20 (35%) | — | 40 (30%) | 17 (47) |
| pT4 | — | 1 (2%) | — | 6 (5%) | — |
| No data | 4 (4%) | 2 (2%) | — | — | — |
| Follow-up | |||||
| Endpoint | Recurrence | BCR | PCa-death | BCR | BCR |
| Occurred | 45 (48%) | 29 (52%) | 165 (59%) | 27 (21%) | 22 (61%) |
| Not occurred | 48 (51%) | 27 (48%) | 116 (41%) | 104 (79%) | 14(39%) |
| No data | 1 (1%) | — | — | — | — |
Abbreviations: BCR – biochemical recurrence, PCa-death – prostate cancer-specific death.
aIn Erho et al. and Mortensen et al.: Low Grade Group 1–3 and high Grade Group 4–5 (due to lack of information to separate Grade Group 2 and 3).
bIn Erho et al. metastatic progression at 10-year patient follow-up.
cClinical T-stage.